{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"PFS2 was defined as the time from randomization to subsequent disease progression after initiation of new anti-cancer therapy, or death from any cause, whichever occurred first, by investigator assessment. As a result of a full clinical hold by FDA that led to discontinuation of study enrollment, no data was collected for analysis of PFS2.","groups":[{"description":"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG000","title":"Pembrolizumab+Pomalidomide+Dexamethasone"},{"description":"Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG001","title":"Standard of Care (SOC) Pomalidomide+Dexamethasone"}],"populationDescription":"The analysis population was to include all randomized participants. Study treatment was terminated early and no data was collected for analysis of PFS2.","reportingStatus":"POSTED","timeFrame":"Up to approximately 30 months","title":"Second Progression Free Survival (PFS2)","type":"SECONDARY"}